Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Copaxone And Complex Generics: Difficult-To-Copy Does Not Mean Impossible

This article was originally published in RPM Report

Executive Summary

FDA’s approval of the first ANDA for an MS therapy signals the agency’s determination to find a way to get generic versions of complex drugs to market. What if any lessons does that hold for biosimilars?

Advertisement

Related Content

Pre-ANDA Meeting Goals May Be Created In GDUFA II
GDUFA II: Priority Reviews Considered For Some ANDAs
Copaxone Generics: FDA Approval Standards Defy Teva’s Argument On Complexity
FDA's Balancing Act: Early Hints at a Biosimilars

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079860

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel